Key facts
- It has raised $1.7M across 3 recorded rounds; the latest was Seed Round ($600K) in Jan 2025.
- Notable investors include Backed, Healthspan Capital, Immortal Dragons, VitaDAO.
- Etheros Pharmaceuticals has filed 3 Form Ds with the SEC since 2023, most recently Jun 2025 ($600K sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Etheros Pharmaceuticals
Funding rounds
3 roundsAbout Etheros Pharmaceuticals
Developer of small-molecule drugs designed to mimic endogenous enzymes for neuroprotection and healthspan improvement. The company platform offers compounds that prevent oxidative and inflammatory injury and extend lifespan, enabling healthcare researchers to advance in treating neural sensitivity and promoting longevity.
- Sector
- Healthcare
- HQ
- Nashville, TN, United States
- Founded
- 2022
- Website
- etherospharma.com/
- Ownership
- Privately Held (backing)
Etheros Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Etheros Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Etheros Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.